Organ procurement coordinators must treat various cardiac dysrhythmias (arrhythmias), including rhythm disturbances that may cause or follow a cardiac arrest, in about 15% to 50% of donors. Treatment decisions should be based on the particular dysrhythmia and its effect on donor blood pressure. Medications selected should be effective but short acting. In this article, data available in publications located through a PubMed search are reviewed and specific dysrhythmias that are likely to occur during donor care are described. Treatment recommendations are based on guidelines from the American Heart Association.
Get full access to this article
View all access options for this article.
References
1.
NygaardCETownsendRNDiamondDL. Organ donor management and organ outcome: A 6-year review from a level I trauma center. J Trauma.1990;6:728–732.
2.
LogigianELRopperAH. Terminal electrocardiographic changes in brain-dead patients. Neurology.1985;35:915–918.
3.
DroryYOuaknineGKosaryIZKellermannJJ. Electrocardiographic findings in brain death: Description and presumed mechanism. Chest.1975;67:425–432.
4.
MuhlbergJWagnerWRohlingRLinkJNeumayerHH. Hemodynamic and metabolic problems in the preparation for organ donation. Transplant Proc.1986;18:391–393.
5.
OuaknineGE. Cardiac and metabolic alterations in brain death: Discussion paper. Ann N Y Acad Sci.1978;315:252–256.
6.
DujardinKSMcCullyRBWijdicksEFM. Myocardial dysfunction associated with brain death: Clinical, echocardiographic, and pathologic features. J Heart Lung Transplant.2001;20:350–357.
7.
GrieppRBStinsonEBClarkDADongEShumwayNE. The cardiac donor. Surg Gynecol Obstet.1971;133:792–798.
8.
DosemeciLYilmazMCengizMDoraBRamazanogluA. Brain death and donor management in the intensive care unit: Experiences over the last 3 years. Transplant Proc.2004;36:20–21.
9.
ShewmonDA. Chronic “brain death”: Meta-analysis and conceptual consequences. Neurology.1998;51:1538–1545.
10.
PownerDJBernsteinIM. Extended somatic support for pregnant women after brain death. Crit Care Med.2003;31:1241–1249.
11.
KinoshitaYOkamotoKYahataK. Clinical and pathological changes of the heart in brain death maintained with vasopressin and epinephrine. Path Res Pract.1990;186:173–179.
12.
IwaiASakanoTUenishiMSugimotoHYoshiokaTSugimotoT. Effects of vasopressin and catecholamines on the maintenance of circulatory stability in brain-dead patients. Transplantation.1989;48:613–617.
13.
SadowskiJWierzbickiKPrzybylowskiP. Does the episode of cardiopulmonary resuscitation in cardiac donors increase the risk of heart transplantation?Przegl Lek.2003;60:76–79.
14.
TotsukaEFungJJUrakamiA. Influence of donor cardiopulmonary arrest in human liver transplantation: Possible role of ischemic preconditioning. Hepatology.2000;31:577–580.
15.
SweeneyMSLammermeierDEFrazierOHBurnettCMHauptHMDuncanJM. Extension of donor criteria in cardiac transplantation: Surgical risk versus supply-side economics. Ann Thorac Surg.1990;50:7–11.
16.
DelaunayLDenisVDarmonPLCatoirePBonnetF. Initial cardiac arrest is a risk factor for failure of organ procurement in brain-dead patients. Transplant Proc.1996;28:2894.
17.
SolomonNAMcGivenJRAlisonPM. Changing donor and recipient demographics in a heart transplantation program: Influence on early outcome. Ann Thorac Surg.2004;77:2096–2102.
18.
de BegonaJAGundrySRRazzoukAJBoucekMMKawauchiMBaileyLL. Transplantation of hearts after arrest and resuscitation: Early and long-term results. J Thorac Cardiovasc Surg.1993;106:1196–1201.
19.
NovitzkyDWicombWNCooperDKCRoseAGFraserRCBarnardCN. Electrocardiographic, hemodynamic and endocrine changes occurring during experimental brain death in the chacma baboon. Heart Transplant.1984;4:63–69.
20.
ShivalkarBVan LoonJWielandW. Variable effects of explosive or gradual increase of intracranial pressure on myocardial structure and function. Circulation.1993;87:230–239.
21.
PowerBMVan HeerdenPV. The physiological changes associated with brain death: Current concepts and implications for treatment of the brain dead organ donor. Anaesth Intensive Care.1995;23:26–36.
22.
NovitzkyDHorakACooperDKRoseAG. Electrocardiographic and histopathologic changes developing during experimental brain death in the baboon. Transplant Proc.1989;21:2567–2569.
23.
BlackPM. Brain death. N Engl J Med.1978;299:338–344.
24.
SmithM. Physiologic changes during brain stem death: Lessons for management of the organ donor. J Heart Lung Transplant.2004;23:S217–S222.
25.
PownerDJ. Treatment goals during care of adult donors that can influence outcomes of heart transplantation. Prog Transplant.2005;15:226–232.
26.
SzaboG. Physiologic changes after brain death. J Heart Lung Transplant.2004;23:S223–S226.
27.
PownerDJKellumJADarbyJM. Abnormalities in fluids, electrolytes, and metabolism of organ donors. Prog Transplant.2000;10:88–96.
28.
PownerDJDarbyJMKellumJA. Proposed treatment guidelines for donor care. Prog Transplant.2004;14:16–28.
29.
HoltDWTuckerGTJacksonPR. Amiodarone pharmacokinetics. Am Heart J.1983;106:840–847.
30.
VaghadiaH. Atropine resistance in brain-dead organ donors. Anesthesiology.1986;65:711–712.
31.
TriganoJABirkuiPJMugicaJ. Noninvasive transcutaneous cardiac pacing: Modern instrumentation and new perspectives. Pacing Clin Electrophysiol.1992;15:1937–1943.
32.
WiestD. Esmolol: A review of its therapeutic efficacy and pharmacokinetic characteristics. Clin Pharmacokinet.1995;28:190–202.
33.
HarringtonC. Managing hypertension in patients with stroke: Are you prepared for labetalol infusion?Crit Care Nurse.2003;23:30–38.
34.
GabrielliAGallagherTJCarusoLJBennettNTLayonAJ. Diltiazem to treat sinus tachycardia in critically ill patients: A four-year experience. Crit Care Med.2001;29:1874–1879.
35.
PageRL. Newly diagnosed atrial fibrillation. N Engl J Med.2004;351:2408–2416.
36.
Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 6, advanced cardiovascular life support: Section 2, defibrillation. Circulation.2000;102(suppl 1):I90–I94.
37.
MarikPEZalogaGP. The management of atrial fibrillation in the ICU. J Intensive Care Med.2000;15:181–190.
38.
RogersKCWolfeDA. Ibutilide: A class III rapidly acting antidysrhythmic for atrial fibrillation or atrial flutter. J Emerg Med.2001;20:67–71.
39.
KarthGDGeppertANeunteuflT. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias. Crit Care Med.2001;29:1149–1153.
40.
ChowM. Intravenous amiodarone: Pharmacology, pharmacokinetics and clinical use. Ann Pharmacother.1996;30:637–643.
41.
HughesMBinningA. Intravenous amiodarone in intensive care: Time for a reappraisal?Intensive Care Med.2000;26:1730–1739.
42.
Blomstrom-LundqvistCScheinmanMMAliotEM. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias—executive summary. J Am Coll Cardiol.2003;42:1493–1531.
43.
Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 6, advanced cardiovascular life support: Section 5, pharmacology I: Agents for arrhythmias. Circulation.2000;102(suppl 1):I112–I128.
